ImmuCell reports 46% jump in third-quarter 2026 product sales

ImmuCell Corporation announced preliminary, unaudited sales results for the third quarter of 2026 on October 12, 2026. Total sales for the three months ended September 30, 2026 were $8.0 million, a 46.0% increase compared to the same period in 2025.¹ Domestic sales were $6.9 million, a 29.2% increase compared to 2025, according to Chief Financial Officer Timothy Fiori.¹

Fiori noted that the comparative sales growth was aided, in part, by depressed sales levels in the third quarter of 2025 caused by high distributor purchases in the second quarter of 2025.¹ Total sales for the nine months ended September 30, 2026 were $25.6 million, a 27.8% increase compared to the same nine-month period in 2025.¹

President and CEO Olivier te Boekhorst said the third quarter growth reflects the results of the company's sales team expansion and continuous improvements in commercial execution, supported by improved ability to reliably manufacture product to meet customer demand.¹ He added that growth was broad-based across the portfolio, with Tri-Shield growing at 51% over the third quarter of 2025, Dual-Force at 36%, and the recently launched functional feed line at 37%.¹

ImmuCell said it will change its disclosure practices going forward. Management decided to discontinue early sales reporting in the future, in line with standard SEC reporting practices, and will instead report revenue along with full financial metrics and market and distribution level information at regular quarterly reporting events.¹ The company plans to discuss revenue drivers and complete financial results for the quarter and nine months ended September 30, 2026 on a conference call scheduled for Friday, November 13, 2026 at 9:00 AM ET.¹